

BAB 5

SARAN

5.1 Saran

Setelah melaksanakan Praktek Kerja Profesi Apoteker (PKPA) di Rumah Sakit Umum Daerah (RSUD) R.T. Notopuro Sidoarjo selama 8 minggu, berikut beberapa saran yang dapat diberikan:

1. Untuk calon apoteker, dapat mempelajari terlebih dahulu peraturan perundangan, standar pelayanan, dan dasar ilmu penunjang pelayanan di rumah sakit sebelum pelaksanaan PKPA. Hal ini bertujuan untuk membantu proses diskusi bersama dengan preceptor.
2. Untuk calon apoteker, dapat mempelajari terlebih dahulu terkait pelayanan farmasi klinis di rumah sakit sebelum melaksanakan PKPA. Hal ini bertujuan untuk membantu proses diskusi bersama dengan preceptor.
3. Untuk RSUD R.T. Notopuro Sidoarjo, instalasi farmasi dapat meningkatkan layanan dengan menentukan stok minimum untuk melakukan permintaan kepada gudang yang disertai dengan *alert stock*. Hal ini bertujuan untuk meningkatkan kecepatan layanan resep.

DAFTAR PUSTAKA

- Abishek, A. and Venkateswaramurthy, N. 2023, A review on antibiotics induced nephrotoxicity, *Int J Basic Clin Pharmacol*, **12(4)**: 600-606.
- American Pharmacist Association. 2014, *Drug Information Handbook*, 24th ed., Lexicomp, US.
- BCRenal, 2023, *Management of Constipation in Patients with Chronic Kidney Disease*.
- Beta, J., Simbolon, O., and Butar-Butar, M. 2022, Antibiotic Use in Diabetes Mellitus Patients with Gangrene at Abdoel Wahab Sjahranie Samarinda Hospital, *Science of Pharmacy*, 65-69.
- Bijie, H., Kulpradist, S., Manalaysay, M. and Kusumo, A. 2005, In vitro activity, pharmacokinetics, clinical efficacy, safety and pharmacoeconomics of ceftriaxone compared with third and fourth generation cephalosporins: Review, *Journal of Chemotherapy*, **17(1)**: 3-24.
- Bird, S., Etminan, M., Brophy, J., Hartzema, A., and Delaney, J. 2013, Risk of Acute Kidney Injury Associated with the Use of Fluoroquinolones, *Cmaj*, **9**: 185.
- BNF, 2022, British National Formulary, 83th Edition, London: BMJ Publishing Group.
- BNF, 2018, *British National Formulary*, 80th ed., BMJ Group, London).
- Brown BD, Hood Watson KL, 2025. Cellulitis. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK549770/>.
- Cha, R., Park, S., and Camilleri, M. 2023, Constipation in Patients with Chronic Kidney Disease, *J Neurogastroenterol Motil*, **29(4)**: 428-435.
- Chen, R., Suchard, M. A., Krumholz, H. M., Schuemie, M. J., Shea, S., Duke, J., ... & Hripcsak, G. 2021, Comparative first-line effectiveness and safety of ACE (angiotensin-converting enzyme) inhibitors and angiotensin receptor blockers: a multinational cohort study, *Hypertension*, **78(3)**: 591-603.
- Cho, Y., Lee, Y., Shin, J., Jung, H., Park, S., *et al.* 2023, 2022 Seoul Consensus on Clinical Practice Guidelines for Functional Constipation, *J Neurogastroenterol Motil*, **29(3)**: 271-305.
- Dipiro, J.T, *et al.* 2023, *Dipiro's Pharmacotherapy: A Pathophysiologic Approach 12th ed*, McGraw-Hill, New York.
- Evans, M., Berry, S., Malkin, S. J. P., Hunt, B., & Sharma, A. 2023, Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide 1 mg Versus Liraglutide 1.8 mg: A Health Economic Analysis in the UK. *Diabetes therapy : research, treatment and education of diabetes and related disorders*, **14(6)**, 1005–1021.
- Famularo, G. and Simone, C. 2002, Nephrotoxicity and Purpura Associated with Levofloxacin, *The Annals of Pharmacotherapy*, **36**: 1380-1382.
- Feng, Qianqiu, Li, Biyun, Lin, Jiating, Zou, Li, Xu, Wen, Zeng, Longyi, Li, Ping, Lin, Shuo, 2025, Insulin Requirement Profiles of Short-Term Continuous Subcutaneous Insulin Infusion Therapy in Patients With Type 2 Diabetic Nephropathy, *International Journal of Endocrinology*, 8403917.

- Gerdes, C., Müller, N., Wolf, G., & Busch, M. 2023, Nephroprotective Properties of Antidiabetic Drugs, *Journal of Clinical Medicine*, **12(10)**: 3377.
- Gorgojo-Martínez, J. J., Malkin, S. J. P., Martín, V., Hallén, N., & Hunt, B. 2019, Assessing the cost-effectiveness of a once-weekly GLP-1 analogue versus an SGLT-2 inhibitor in the Spanish setting: Once-weekly semaglutide versus empagliflozin, *Journal of Medical Economics*, **23(2)**: 193–203.
- Hanna, S. M., Rabea, H. M., Abdelrahim, M. E. A., & Mahmoud, H. B. 2024, Safety and efficacy of candesartan versus valsartan combined with amlodipine on peripheral and central blood pressure, *Hypertension y riesgo vascular*, **41(1)**: 17-25.
- Herman LL, Weber P, Bashir K. 2025, Hydrochlorothiazide. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK430766/>.
- Hidayat, R. et al, 2022, Clopidogrel resistance among ischemic stroke patients and its risk factors in Indonesia, *Acta Med Acad*, 2022;51(1):29–34.
- Hong, D., Si, L., Jiang, M. *et al.* 2019, Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review, *PharmacoEconomics*, **37**: 777–818.
- Jin, Z. J., & Wang, G. Z. 2023, Clinical Efficacy of Dapagliflozin in the Treatment of Patients with Diabetic Nephropathy and Its Effect on Proteinuria Level, *Diabetes, metabolic syndrome and obesity : targets and therapy*, **16**: 2167–2175.
- Karimi, M. A., Gholami Chahkand, M. S., Dadkhah, P. A., Sheikhzadeh, F., Yaghoubi, S., Esmaeilpour Moallem, F., Deyhimi, M. S., Arab Bafrani, M., Shahrokhi, M., & Nasrollahizadeh, A. 2025, Comparative effectiveness of semaglutide *versus* liraglutide, dulaglutide or tirzepatide: a systematic review and meta-analysis, *Frontiers in pharmacology*, **16**: 1438318.
- KDIGO, 2024, KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease, *Kidney International*, **105(4)**: S117-S314.
- Kementerian Kesehatan Republik Indonesia, 2023, *Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.01.07/MENKES/1634/2023 Tentang Pedoman Nasional Pelayanan Kedokteran Tata laksana Penyakit Ginjal Kronik*, Jakarta.
- Kemenkes RI, 2021, *Panduan Penatagunaan Antimikroba di Rumah Sakit, edisi 1*, Jakarta.
- Kemenkes, 2021, *Peraturan Menteri Kesehatan Republik Indonesia Nomor 28 Tahun 2021 tentang Pedoman Penggunaan Antibiotik*, Jakarta.
- Kemenkes RI, 2020, *Pedoman Nasional Pelayanan Kedokteran (PNPK) Tata Laksana Diabetes Melitus Tipe 2 Dewasa*, Jakarta.
- Khan TM, Patel R, Siddiqui AH. 2025, Furosemide. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK499921/>.
- Khayyat, A., Abbas, H., Mohamed, M., Asfour, H., Khayat, M., Ibrahim, S., Youns, M., Khafagy, E., Lila, A., Safo, M., Hegazy, W. 2021, Not Only Antimicrobial: Metronidazole Mitigates the Virulence of *Proteus mirabilis* Isolated from Macerated Diabetic Foot Ulcer, *Applied Sciences*, **11**: 6847.
- Ku, E. J., Lee, D. H., Jeon, H. J., & Oh, T. K. 2019, Empagliflozin versus dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin, glimepiride and

- dipeptidyl peptide 4 inhibitors: A 52-week prospective observational study, *Diabetes research and clinical practice*, **151**: 65–73.
- Lin, C., Huang, SC, Chen, JJ, Li, YR, Yen, CL, Ho, WY, & Hsiao, CC. 2025, Risiko Diabetes Melitus Onset Baru dan Luaran Kardiovaskular Telmisartan pada Pasien Hipertensi.
- Lucas, G., Leitao, A., Alencar, R., Xavier, R., Daher, E., and Junior, G. 2018, Pathophysiological aspects of nephropathy caused by non-steroidal anti-inflammatory drugs, *J Bras Nefrol*, **41(1)**: 124-130.
- Marti-Carvajal, A.J., Valli, V., Marti-Amarista, C.E., Sola, I., Martí-Fàbregas, J and Cosp, X.B, 2020, Citicoline for treating people with acute ischemic stroke, *Cochrane Database Syst Rev*, 8(8): CD013066.
- Mazza, A., Sacco, A. P., Townsend, D. M., Bregola, G., Contatto, E., Cappello, I., Schiavon, L., Ramazzina, E., Rubello, D. (2017). Cost-benefit effectiveness of angiotensin-II receptor blockers in patients with uncomplicated hypertension: A comparative analysis. *Biomedicine & Pharmacotherapy*, 90: 665-669.
- McEvoy, G. K., *et al.* 2011, Drug Infomation Essentials. Bethesda: American Society of Health-System Pharmacists.
- McLendon K, Preuss CV. 2025, Atropine. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK470551/>.
- McMahon RS, Bashir K. 2025, Potassium Chloride. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK557785/>.
- Nechi, R. N., Rane, A., Karaye, R. M., Ndikumukiza, C., Alsaahli, S., Jatau, A. I., Zoni, C. R., Alanzi, A., Karaye, I. M., & Yunusa, I. 2023, Cost-Effectiveness of Dapagliflozin vs Empagliflozin for Treating Heart Failure With Reduced Ejection Fraction in the United States, *Clinical therapeutics*, **45(7)**: 627–632.
- Perkeni, 2021, *Pedoman Pengelolaan dan Pencegahan Diabetes Melitus Tipe 2 di Indonesia*, Jakarta.
- Perhimpunan Reumatologi Indonesia, 2024, Pedoman Diagnosis dan Tatalaksana Hiperurisemia & Arthritis Gout.
- Purvey, M and Allen, G. 2017, Managing acute pulmonary oedema, *Austrialian Prescriber*, 40(2):59–63.
- Rimbun, S and Anto, E.J. 2024, Citicoline in acute ischemic stroke: case report, *Indonesian Journal of Medicine*, 09(03): 302-309.
- Rondon H, Badireddy M. 2025, Hyponatremia. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK470386/>.
- Senneville, E., Albalawi, Z., Asten, S., Abbas, Z., Allison, G., Aragon-Sanchez, J., Embil, J., Laver, L., ALhasan, M., Oz, O., Uckay, I., Urbancic-Rovan, V., Xu, Z, and Peters, E. 2023, IWGDF/IDSA Guidelines on the Diagnosis and Treatment of Diabetes-related Foot Infections (IWGDF/IDSA 2023), *IDSA Guidelines*.
- Sharma B, Chalikwar R, Bhalerao S, *et al.* 2024, Cefotaxime Versus Ceftriaxone: A Comprehensive Comparative Review, *Cureus*, **16(9)**: e69146.

- Tokunaga, M., Kabashima, N., Serino, R., Shibata, T., Matsumoto, M., Miyamoto, T., ... & Tamura, M. 2010, Renoprotective effects of telmisartan in patients with advanced chronic kidney disease, *Clinical nephrology*, **73(2)**: 139-146.
- Viljoen, A., Chubb, B., Malkin, S. J. P., Berry, S., Hunt, B., & Bain, S. C. (2023). The long-term cost-effectiveness of once-weekly semaglutide 1 mg vs. dulaglutide 3 mg and 4.5 mg in the UK, *The European journal of health economics: HEPAC: health economics in prevention and care*, **24(6)**: 895–907.
- Winiarska, A., Knysak, M., Nabrdalik, K., Gumprecht, J., & Stompór, T. 2021, Inflammation and Oxidative Stress in Diabetic Kidney Disease: The Targets for SGLT2 Inhibitors and GLP-1 Receptor Agonists *International Journal of Molecular Sciences*, **22(19)**: 10822.
- Yu, J. H., Park, S. Y., Lee, D. Y., Kim, N. H., & Seo, J. A. 2022, GLP-1 receptor agonists in diabetic kidney disease: current evidence and future directions, *Kidney research and clinical practice*, **41(2)**: 136–149.
- Yuan, M., Wang, B. And Tan, S., 2018, Mecobalamin and early functional outcomes of ischemic stroke patients with H-type hypertension, *Rev Assoc Med Bras* 2018, 64(5):428-432.
- Zhang, Z., Yang, H., & Guo, H. 2024, Comparative efficacy and safety of six angiotensin II receptor blockers in hypertensive patients: a network meta-analysis, *International Journal of Clinical Pharmacy*, **46(5)**: 1034-104.